These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 36925938)

  • 21. Regulatory T Cells Increase After rh-MOG Stimulation in Non-Relapsing but Decrease in Relapsing MOG Antibody-Associated Disease at Onset in Children.
    Horellou P; de Chalus A; Giorgi L; Leroy C; Chrétien P; Hacein-Bey-Abina S; Bourgeois C; Mariette X; Serguera C; Le Grand R; Deiva K
    Front Immunol; 2021; 12():679770. PubMed ID: 34220827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
    Gericke FC; Hanson JVM; Hackenberg A; Gerth-Kahlert C
    Eur J Paediatr Neurol; 2024 Jan; 48():113-120. PubMed ID: 38217965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood parameters in pediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Peternell A; Lechner C; Breu M; Preisel M; Schimmel M; Eisenkölbl A; Zobel J; Wendel EM; Reindl M; Rostásy K; Baumann M
    Eur J Paediatr Neurol; 2024 May; 50():86-95. PubMed ID: 38705015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD).
    Li Y; Liu X; Wang J; Pan C; Tang Z
    Front Aging Neurosci; 2022; 14():850743. PubMed ID: 35370624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebral Cortical Encephalitis and Other Meningocortical Manifestations of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in Children: Case Series and Review of the Literature.
    Carozza RB; Bolte K; Greene EB; Reddy SB; Vu NH
    J Child Neurol; 2024 Nov; 39(13-14):487-493. PubMed ID: 39311053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
    Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
    Banwell B; Bennett JL; Marignier R; Kim HJ; Brilot F; Flanagan EP; Ramanathan S; Waters P; Tenembaum S; Graves JS; Chitnis T; Brandt AU; Hemingway C; Neuteboom R; Pandit L; Reindl M; Saiz A; Sato DK; Rostasy K; Paul F; Pittock SJ; Fujihara K; Palace J
    Lancet Neurol; 2023 Mar; 22(3):268-282. PubMed ID: 36706773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
    Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
    Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical characteristics of myelin oligodendrocyte glycoprotein antibody associated myelitis].
    Zhangbao BJZ; Zhou L; Wang L; Huang WJ; Zhao CB; Lu JH; Quan C
    Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(5):334-338. PubMed ID: 32074775
    [No Abstract]   [Full Text] [Related]  

  • 35. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
    Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
    Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases.
    Ziaei A; Nasr Z; Hart J; Francisco C; Rutatangwa A; Leppert D; Kuhle J; Flanagan E; Waubant E
    Mult Scler Relat Disord; 2023 Jun; 74():104704. PubMed ID: 37031551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MOG CNS Autoimmunity and MOGAD.
    Moseley CE; Virupakshaiah A; Forsthuber TG; Steinman L; Waubant E; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200275. PubMed ID: 38996203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases.
    Guzmán J; Vera F; Soler B; Uribe-San-Martin R; García L; Del-Canto A; Schlatter A; Salazar M; Molt F; Ramirez K; Marín J; Pelayo C; Cruz JP; Bravo-Grau S; Cárcamo C; Ciampi E
    Mult Scler Relat Disord; 2023 Jan; 69():104442. PubMed ID: 36521387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
    Goldman-Yassen A; Lee A; Gombolay G
    Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and radiological spectrum of anti-myelin oligodendrocyte glycoprotein (MOG) antibody encephalitis: single-center observational study.
    Salunkhe M; Gupta P; Singh RK; Tayade K; Goel V; Agarwal A; Das A; Elavarasi A; Pandit AK; Vibha D; Garg A; Sebastian LJD; Bhatia R; Tripathi M; Gaikwad S; Srivastava M
    Neurol Sci; 2023 Jul; 44(7):2475-2489. PubMed ID: 36810716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.